Daily Hong Kong Stock Market News Briefing (January 22, Wednesday)

USHK News
2025.01.22 01:02

Individual Stock News

  1. Zijin Mining (02899.HK): The company expects to achieve a net profit attributable to shareholders of approximately RMB 32 billion for the fiscal year 2024, an increase of approximately RMB 10.881 billion compared to the same period last year, representing a year-on-year increase of approximately 51.5%.

  2. China Shenhua (01088.HK): The State Energy Group Company will transfer its 100% equity in Hangjin Energy to the company, with a transfer price of RMB 853 million, which will be paid using the company's own funds.

  3. Sunac China (01918.HK): The domestic debt restructuring plan has been approved by relevant creditors, which will adjust the principal and interest repayment arrangements for ten bonds and provide restructuring options including bond buybacks, stock and/or stock economic benefit rights redemption, and debt-for-equity swaps.

  4. Anton Oilfield Services Group (03337.HK): New orders for the fourth quarter of 2024 amounted to RMB 2.651 billion, a year-on-year increase of 73.4%. New orders in the Iraqi market amounted to RMB 1.679 billion, a significant year-on-year increase of 102.5%.

  5. Sun Hung Kai Properties (00086.HK) has committed USD 100 million to invest in the WCD fund and has pledged to invest AUD 25 million in the Wentworth GP Trust Fund as cornerstone investment.

  6. COMEC (00317.HK): The company expects to achieve a net profit attributable to the parent company of RMB 350 million to 400 million for the fiscal year 2024, representing a year-on-year increase of 628.14% to 732.16%.

  7. China Aircraft Leasing (01848.HK): A wholly-owned subsidiary of the company has entered into a "Aircraft Purchase Agreement" with an independent third party to purchase two aircraft, selling two Boeing 737-800 aircraft, with the purchase expected to be completed by the end of August 2025.

  8. JP Morgan increased its holdings in Weichai Power (02338.HK) by 2,823,892 shares at a price of HKD 13.3454 per share, totaling approximately HKD 37.686 million.

  9. Ascletis Pharma (01672.HK): The small molecule oral GLP-1R agonist ASC30 has achieved positive results in the U.S. Phase Ia single-dose escalation study and provided project progress updates

Source: USHK News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.